(1276.HK; 600276.SH) delivered a piece of good news for investors with positive trial data for a dual-acting obesity drug ...

Tirzepatide yielded greater cardiometabolic benefits, especially in total cholesterol, LDL cholesterol, and weight loss, among women than men.

While lifestyle interventions such as diet and exercise remain first-line treatments, long-term success is often limited due to frequent weight regain once interventions stop. Tirzepatide is a dual ...